Real-World Outcomes of Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Third-Line Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Single-Center Study

Background: Diffuse large B-cell lymphoma (DLBCL) is the most common diagnosed aggressive B-cell lymphoma, with poor outcomes in those who experience relapsed or refractory (R/R) disease. Landmark clinical trials have demonstrated the efficacy and safety of anti-CD19 chimeric antigen receptor (CAR)...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Aishwarya Sridhar, Thomas S. Gunning, Alexandra Della Pia, Xiaopei Zhang, Jaeil Ahn, Brittany Sinclaire, Brittany Lukasik, Christina Cho, Michele L. Donato, Sukhdeep Kaur, Hyung C. Suh, Lori A. Leslie, Tatyana A. Feldman, Andre H. Goy, Andrew Ip
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	MDPI AG 2025-01-01
Serie:	Hemato
Ämnen:	diffuse large B-cell lymphoma DLBCL non-Hodgkin lymphoma NHL cytokine release syndrome CRS
Länkar:	https://www.mdpi.com/2673-6357/6/1/3
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!